Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 382 clinical trials
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

interleukin-2 works in treating patients with metastatic kidney cancer.

hypertension
platelet count
arrhythmia
carcinoma in situ
white blood cell count
  • 17 views
  • 07 Nov, 2020
  • 2 locations
  • 0 views
  • 25 Jan, 2021
  • 26 locations
Ketogenic Diet for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma

The purpose of this study is to evaluate the tolerance of one year of ketogenic diet associated with vitamin supplementation in patients treated for a metastatic renal cell carcinoma.

  • 0 views
  • 26 Jan, 2021
  • 1 location
Bevacizumab in Advanced Hepatocellular Carcinoma

liver cancer. Bevacizumab is an angiogenesis inhibitor already successfully used in patients with colorectal and renal cancers.

bevacizumab
alpha fetoprotein
platelet count
biliary tract cancer
primary liver cancer
  • 14 views
  • 07 Nov, 2020
  • 1 location
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Combination treatment of Durvalumab with chemoradiotherapy is ongoing for head/neck cancer, renal cell carcinoma, melanoma, and non-small cell lung cancer (NCT02318771) and pancreatic cancer

  • 0 views
  • 23 Jan, 2021
  • 1 location
Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma

molecule multi-kinase inhibitor of VEGFR, PDGFR and RAF with demonstrated activity in the treatment of renal cell cancer (9). Preclinical studies suggest that the combination of Sorafenib with

measurable disease
soft tissue sarcoma
ewing's sarcoma
doxorubicin
platelet count
  • 13 views
  • 07 Nov, 2020
  • 1 location
Molecular Determinants for Therapy Response on Renal Cell Carcinoma

Aim of the scientific analysis is to find biological factors (biomarkers) allowing a prediction of disease progression and a better choice of therapy. After diagnosis the kidney and the tumor will be removed by standard surgery followed by drug therapy. Within surgery remaining tumor tissue will be used for the …

bevacizumab
sunitinib
systemic therapy
kidney cancer
biological factors
  • 28 views
  • 08 Nov, 2020
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

This study is intend to explore the efficacy and safety of combined treatment of camrelizumab and bevacizumab in adult patients with recurrent glioblastoma.

  • 0 views
  • 17 Jul, 2021
  • 1 location
A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy.

  • 47 views
  • 22 Jan, 2021
  • 5 locations
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: ribociclib everolimus dexamethasone

  • 13 views
  • 06 Aug, 2021
  • 10 locations